Top

Journal of Endocrinological Investigation

Published in:

01-03-2022 | Polycystic Ovary Syndrome | Original Article

The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial

Authors: V. Soldat-Stanković, S. Popović-Pejičić, S. Stanković, A. Prtina, G. Malešević, J. Bjekić-Macut, S. Livadas, S. Ognjanović, G. Mastorakos, D. Micić, D. Macut

Published in: Journal of Endocrinological Investigation | Issue 3/2022

Abstract

Purpose

To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI).

Methods

In this open label, parallel randomized clinical trial, 66 women with PCOS (33 normal-weight and 33 overweight/obese) were randomized to either MI (4 g/day) or MET (1500 mg/day) for a period of 6 months. Serum concentration of adiponectin, hormonal and metabolic laboratory outcomes and clinical assessment of BMI, body composition and Ferriman–Gallwey score (FG score) were evaluated before and after treatment.

Results

After the 6-month intervention, comparison between MET and MI in time to treatment analysis showed no significant differences between the two treatments for all analyzed parameters. Only borderline significantly lower AUC glucose was found in the MET group in comparison to the MI group (p = 0.071). The main effect of treatment was shown for glucose concentration at 120 min OGTT (p = 0.032) and testosterone (p = 0.002). The main effect of time was shown for body mass (p = 0.004), waist circumference (p < 0.001), BMI (p = 0.003), body fat mass (p = 0.001), adiponectin (p = 0.020), fasting glucose (p = 0.001), testosterone (p = 0.015), SHBG (p = 0.013), 17OH progesterone (p = 0.008), LH (p = 0.004) and estradiol (p = 0.014).

Conclusion

Our study showed similar effects of MET and MI on BMI, body composition, hormonal profile, metabolism of glucose and insulin, and adiponectin level. The two insulin sensitizers, MET and MI, were useful in reducing BMI and improving body composition without significant differences between the two treatments in PCOS women.

Trial registration

ISRCTN13199265. Trial registration date: 14.04.2021. (ISRCTN Registry), retrospectively registered.

Conway G, Dewailly D, Diamanti-Kandarakis E et al (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1-29. https://doi.org/10.1530/EJE-14-0253CrossRefPubMed

Echiburú B, Pérez-Bravo F, Galgani JE et al (2018) Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids 130:15–21. https://doi.org/10.1016/j.steroids.2017.12.009CrossRefPubMed

Barber TM, Franks S (2013) Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 373:68–76. https://doi.org/10.1016/j.mce.2012.10.010CrossRefPubMed

Panidis D, Tziomalos K, Misichronis G et al (2012) Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 27:541–549. https://doi.org/10.1093/humrep/der418CrossRefPubMed

Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83. https://doi.org/10.1006/bbrc.1999.0255CrossRefPubMed

Tan BK, Chen J, Digby JE et al (2006) Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 49:2723–2728. https://doi.org/10.1007/s00125-006-0419-9CrossRefPubMed

Escobar-Morreale HF, Villuendas G, Botella-Carretero JI et al (2006) Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 21:2257–2265. https://doi.org/10.1093/humrep/del146CrossRefPubMed

Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219-227. https://doi.org/10.1530/REP-14-0435CrossRefPubMed

Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138:269–274. https://doi.org/10.1530/eje.0.1380269CrossRefPubMed

10.

Morley LC, Tang T, Yasmin E et al (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 11:CD003053. https://doi.org/10.1002/14651858.CD003053.pub6CrossRefPubMed

11.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162:193–212. https://doi.org/10.1530/EJE-09-0733CrossRefPubMed

12.

Hamed HO (2013) Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. J Obstet Gynaecol Res 39:1596–1603. https://doi.org/10.1111/jog.12101CrossRefPubMed

13.

Karkanaki A, Piouka A, Katsikis I et al (2009) Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Fertil Steril 92:2078–2081. https://doi.org/10.1016/j.fertnstert.2009.06.034CrossRefPubMed

14.

Polak K, Czyzyk A, Simoncini T, Meczekalski B (2017) New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 40:1–8. https://doi.org/10.1007/s40618-016-0523-8CrossRefPubMed

15.

Bevilacqua A, Bizzarri M (2018) Inositols in insulin signaling and glucose metabolism. Int J Endocrinol 2018:1968450. https://doi.org/10.1155/2018/1968450CrossRefPubMedPubMedCentral

16.

Baillargeon J-P, Diamanti-Kandarakis E, Ostlund RE et al (2006) Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300–305. https://doi.org/10.2337/diacare.29.02.06.dc05-1070CrossRefPubMed

17.

D’Anna R, Santamaria A, Cannata ML et al (2014) Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. Int J Endocrinol 2014:653561. https://doi.org/10.1155/2014/653561CrossRefPubMedPubMedCentral

18.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47. https://doi.org/10.1093/humrep/deh098CrossRef

19.

Escobar-Morreale HF, Carmina E, Dewailly D et al (2012) Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 18:146–170. https://doi.org/10.1093/humupd/dmr042CrossRefPubMed

20.

Macut D, Bačević M, Božić-Antić I et al (2015) Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015:812610. https://doi.org/10.1155/2015/812610CrossRefPubMedPubMedCentral

21.

Sowers MR, Randolph J, Jannausch M et al (2008) Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the “timing hypothesis.” Arch Intern Med 168:2146–2153. https://doi.org/10.1001/archinte.168.19.2146CrossRefPubMedPubMedCentral

22.

Namavar Jahromi B, Dabaghmanesh MH, Parsanezhad ME, Fatehpoor F (2017) Association of leptin and insulin resistance in PCOS: a case-controlled study. Int J Reprod Biomed 15:423–428PubMedPubMedCentral

23.

Naderpoor N, Shorakae S, de Courten B et al (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 21:560–574. https://doi.org/10.1093/humupd/dmv025CrossRefPubMed

24.

Pasquali R, Gambineri A, Biscotti D et al (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774. https://doi.org/10.1210/jcem.85.8.6738CrossRefPubMed

25.

Le Donne M, Metro D, Alibrandi A et al (2019) Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 23:2293–2301. https://doi.org/10.26355/eurrev_201903_17278CrossRefPubMed

26.

Croze ML, Vella RE, Pillon NJ et al (2013) Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem 24:457–466. https://doi.org/10.1016/j.jnutbio.2012.01.008CrossRefPubMed

27.

Gabriely I, Ma XH, Yang XM et al (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2951–2958. https://doi.org/10.2337/diabetes.51.10.2951CrossRefPubMed

28.

Olszanecka-Glinianowicz M, Kuglin D, Dąbkowska-Huć A, Skałba P (2011) Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 154:51–56. https://doi.org/10.1016/j.ejogrb.2010.08.022CrossRefPubMed

29.

Lecke SB, Mattei F, Morsch DM, Spritzer PM (2011) Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril 95:2044–2049. https://doi.org/10.1016/j.fertnstert.2011.02.041CrossRefPubMed

30.

Zulian A, Cancello R, Girola A et al (2011) In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 4:27–33. https://doi.org/10.1159/000324582CrossRefPubMedPubMedCentral

31.

Gagnon J, Sheppard E, Anini Y (2013) Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab 15:276–279. https://doi.org/10.1111/dom.12021CrossRefPubMed

32.

Vrbíková J, Hill M, Stárka L, Vondra K (2002) Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecol Obstet Invest 53:100–104. https://doi.org/10.1159/000053002CrossRefPubMed

33.

Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 22:2967–2973. https://doi.org/10.1093/humrep/dem271CrossRefPubMed

34.

Tagliaferri V, Romualdi D, Immediata V et al (2017) Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol 86:725–730. https://doi.org/10.1111/cen.13304CrossRef

35.

Nestler JE, Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82:4075–4079. https://doi.org/10.1210/jcem.82.12.4431CrossRefPubMed

36.

Hirsch A, Hahn D, Kempná P et al (2012) Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology 153:4354–4366. https://doi.org/10.1210/en.2012-1145CrossRefPubMed

37.

la Marca A, Morgante G, Paglia T et al (1999) Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72:985–989. https://doi.org/10.1016/s0015-0282(99)00407-0CrossRefPubMed

38.

Cho K, Chung JY, Cho SK et al (2015) Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway. Sci Rep 5:8145. https://doi.org/10.1038/srep08145CrossRefPubMedPubMedCentral

39.

Vrbíková J, Hill M, Stárka L et al (2001) The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol 144:619–628. https://doi.org/10.1530/eje.0.1440619CrossRefPubMed

40.

Genazzani AD, Prati A, Santagni S et al (2012) Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 28:969–973. https://doi.org/10.3109/09513590.2012.685205CrossRefPubMed

41.

Artini PG, Di Berardino OM, Papini F et al (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375–379. https://doi.org/10.3109/09513590.2012.743020CrossRefPubMed

42.

Januszewski M, Issat T, Jakimiuk AA et al (2019) Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol 90:7–10. https://doi.org/10.5603/GP.2019.0002CrossRefPubMed

43.

Nestler JE, Unfer V (2015) Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 31:501–505. https://doi.org/10.3109/09513590.2015.1054802CrossRefPubMed

44.

Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691–696. https://doi.org/10.1016/s0015-0282(98)00011-9CrossRefPubMed

45.

Moghetti P, Castello R, Negri C et al (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139–146. https://doi.org/10.1210/jcem.85.1.6293CrossRefPubMed

46.

Pau CT, Keefe C, Duran J, Welt CK (2014) Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab 99:1870–1878. https://doi.org/10.1210/jc.2013-4021CrossRefPubMedPubMedCentral

47.

Hansen M, Palsøe MK, Helge JW, Dela F (2015) The effect of metformin on glucose homeostasis during moderate exercise. Diabetes Care 38:293–301. https://doi.org/10.2337/dc14-1480CrossRefPubMed

48.

Nascimento AD, Silva Lara LA, de Sá J, Rosa-e-Silva AC et al (2013) Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol 29:246–249. https://doi.org/10.3109/09513590.2012.736563CrossRefPubMed

49.

Grigoryan O, Absatarova J, Andreeva E et al (2014) Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol 66:85–89PubMed

50.

Sonntag B, Götte M, Wülfing P et al (2005) Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 84(Suppl 2):1173–1179. https://doi.org/10.1016/j.fertnstert.2005.04.043CrossRefPubMed

51.

Romualdi D, Giuliani M, Cristello F et al (2010) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 93:2303–2310. https://doi.org/10.1016/j.fertnstert.2009.01.114CrossRefPubMed

Title: The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial
Authors: V. Soldat-Stanković
S. Popović-Pejičić
S. Stanković
A. Prtina
G. Malešević
J. Bjekić-Macut
S. Livadas
S. Ognjanović
G. Mastorakos
D. Micić
D. Macut
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keywords: Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Metformin
Insulins
Insulins
Testosterone
Overweight
Published in: Journal of Endocrinological Investigation / Issue 3/2022
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-021-01691-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 3/2022

SIGIS–SIAMS–SIE position statement of gender affirming hormonal treatment in transgender and non-binary people

Effect of a high-fat diet and chromium on hormones level and Cr retention in rats

Reply to the letter to the editor by Mungmunpuntipantip et al.

Deciphering the link between Diabetes mellitus and SARS-CoV-2 infection through differential targeting of microRNAs in the human pancreas

Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma

A dose–response meta-analysis to evaluate the relationship between high-density lipoprotein cholesterol and all-cause and cardiovascular disease mortality

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage